Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on May 4, 2016, reporting events occurring on April 28, 2016. The company, incorporated in Delaware with principal offices in Ashdod, Israel, entered into a Securities Purchase Agreement with accredited investors to raise capital through the issuance of preferred stock and warrants.
Key Financial Metrics
- Gross Proceeds: $1,351,000 received from the sale of 1,351 Units.
- Capital Structure Issued: 1,351 shares of Series C 5.5% Convertible Preferred Stock.
- Conversion Terms: Initial conversion price of $4.50 per share, convertible into an aggregate of 300,223 shares of Common Stock.
- Warrant Terms: Two classes of 5-year warrants issued per unit:
- Series C-1 Warrants: Exercise price of $4.50 per share.
- Series C-2 Warrants: Exercise price of $7.75 per share.
- Total Warrant Coverage: Warrants are exercisable for an aggregate of 600,446 shares of Common Stock.
- Transaction Costs: Placement agent compensation included a 10% cash commission and a 3% non-accountable expense allowance on the aggregate sales price, plus issuance of additional warrants.
Material Changes
This transaction represents the second closing of an offering of Units. The initial closing involved the sale of 1,133 Units on April 14, 2016. As a result of the first closing, the conversion price per share for the Company's existing Series A 5% Convertible Preferred Stock and Series B 5.5% Convertible Preferred Stock was reduced to $4.50 per share.
Outlook, Risks, and Unusual Items
- Unregistered Sale: The Units were sold without registration under the Securities Act of 1933, relying on the Section 4(a)(2) exemption for transactions by an issuer not involving any public offering.
- Registration Rights: The Company entered into a Registration Rights Agreement with the purchasers, substantially identical to the agreement for the prior issuance.
- Placement Agent Warrants: The placement agent received warrants to purchase up to 60,045 shares at $4.50 and 30,022 shares at $7.75. These warrants include full ratchet anti-dilution protection and cashless exercise provisions.
Investor Verification Checklist
- Verify the total dilution impact of the 300,223 convertible shares and 600,446 warrant shares on existing shareholders.
- Confirm the cash balance impact after deducting the 13% total placement agent fees (10% commission + 3% expense allowance).
- Review the "Prior 8-K" filed on April 14, 2016, for details on the initial closing and the specific terms of the Series A and Series B preferred stock conversion price adjustments.
- Assess the liquidity implications of the full ratchet anti-dilution protection granted to the placement agent.